

Special Issue

U.S. Myeloma Innovations Research Collaborative (USMIRC) Collection

Message from the Guest Editor

This Special Issue highlights the collaborative innovation emerging from our integrated myeloma research programs, dedicated to transforming outcomes through next-generation immunotherapy, cellular therapy, and precision-based translational science. Our projects span the full spectrum of immune-based strategies—including CAR-T cells, T-cell engagers (TCEs), bispecific and trispecific platforms, and novel targets such as BCMA, GPRC5D, and emerging noncanonical antigens. In partnership with national and international collaborators across academic centers, cooperative groups, and the U.S. Myeloma Innovations Research Collaborative (USMIRC), our work aims to define mechanisms of resistance, optimize sequencing, and expand access to cutting-edge therapies for patients with multiple myeloma and other plasma cell disorders. Together, these initiatives create a multidisciplinary ecosystem accelerating discovery, clinical translation, and real-world impact.

Guest Editor

Dr. Al-Ola A. Abdallah

Division of Hematologic Malignancies & Cellular Therapeutics,
University of Kansas Medical Center, Westwood, KS 66205, USA

Deadline for manuscript submissions

31 December 2026



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/266454

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncology](https://mdpi.com/journal/currentoncology)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
 2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada
-

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)